CRP and pulmonary arterial hypertension: A small‐scale pilot trial in adult PAH patients showed that IL‐1 receptor blockade by anakinra reduced plasma CRP within 15 days of treatment, yet this did not result in significant hemodynamic or echocardiographic changes.34